161 related articles for article (PubMed ID: 30701988)
1. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
Valle JW; Borbath I; Rosbrook B; Fernandez K; Raymond E
Future Oncol; 2019 Apr; 15(11):1219-1230. PubMed ID: 30701988
[TBL] [Abstract][Full Text] [Related]
2. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.
Fazio N; Martini JF; Croitoru AE; Schenker M; Li S; Rosbrook B; Fernandez K; Tomasek J; Thiis-Evensen E; Kulke M; Raymond E
Future Oncol; 2019 Jun; 15(17):1997-2007. PubMed ID: 31084373
[No Abstract] [Full Text] [Related]
7. Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine Tumors.
Mathew A; Führer D; Lahner H
Horm Metab Res; 2021 Dec; 53(12):794-800. PubMed ID: 34891209
[TBL] [Abstract][Full Text] [Related]
8. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
9. Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study.
Sato K; Toyoshima Y; Moriyama S; Endo Y; Ito T; Ohki E
Cancer Chemother Pharmacol; 2019 Jan; 83(1):201-207. PubMed ID: 30413868
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
Vinik A; Bottomley A; Korytowsky B; Bang YJ; Raoul JL; Valle JW; Metrakos P; Hörsch D; Mundayat R; Reisman A; Wang Z; Chao RC; Raymond E
Target Oncol; 2016 Dec; 11(6):815-824. PubMed ID: 27924459
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
Pellat A; Dreyer C; Couffignal C; Walter T; Lombard-Bohas C; Niccoli P; Seitz JF; Hentic O; André T; Coriat R; Faivre S; Zappa M; Ruszniewski P; Pote N; Couvelard A; Raymond E
Neuroendocrinology; 2018; 107(1):24-31. PubMed ID: 29518779
[TBL] [Abstract][Full Text] [Related]
12. Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
[TBL] [Abstract][Full Text] [Related]
13. Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
Ishak KJ; Rael M; Hicks M; Mittal S; Eatock M; Valle JW
J Comp Eff Res; 2018 Oct; 7(10):947-958. PubMed ID: 30168349
[TBL] [Abstract][Full Text] [Related]
14. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.
Fazio N; Kulke M; Rosbrook B; Fernandez K; Raymond E
Target Oncol; 2021 Jan; 16(1):27-35. PubMed ID: 33411058
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
Invest New Drugs; 2013 Oct; 31(5):1265-74. PubMed ID: 23269537
[TBL] [Abstract][Full Text] [Related]
17. An update on the management of pancreatic neuroendocrine tumors.
Gao L; Natov NS; Daly KP; Masud F; Chaudhry S; Sterling MJ; Saif MW
Anticancer Drugs; 2018 Aug; 29(7):597-612. PubMed ID: 29782352
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
Rinzivillo M; Fazio N; Pusceddu S; Spallanzani A; Ibrahim T; Campana D; Marconcini R; Partelli S; Badalamenti G; Brizzi MP; Catena L; Schinzari G; Carnaghi C; Berardi R; Faggiano A; Antonuzzo L; Spada F; Gritti S; Femia D; Gelsomino F; Bongiovanni A; Ricci S; Brighi N; Falconi M; Delle Fave G; Panzuto F
Pancreatology; 2018 Mar; 18(2):198-203. PubMed ID: 29361429
[TBL] [Abstract][Full Text] [Related]
19. Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature.
Clover T; Abdelkader A; Guru Murthy GS
J Oncol Pharm Pract; 2019 Sep; 25(6):1516-1519. PubMed ID: 30089432
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib in pancreatic neuroendocrine tumors.
Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
